Skip to main content

Indium DTPA In 111

Generic: Indium In-111 Pentetate Disodium

Verified·Apr 23, 2026
Manufacturer
Curium
NDC
17156-251
Route
INTRATHECAL
ICD-10 indication
G91.2

Affordability Check

How much will you actually pay for Indium DTPA In 111?

In 30 seconds, see every legitimate way to afford Indium DTPA In 111 — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Indium DTPA In 111

What is this medication?

Indium DTPA In 111 is a radioactive diagnostic agent used by medical professionals to visualize the movement of cerebrospinal fluid within the central nervous system. It belongs to a class of drugs known as radiopharmaceuticals and contains a small amount of the radioactive isotope Indium-111. The medication is usually administered through a procedure called a lumbar puncture, where it is injected directly into the subarachnoid space surrounding the spinal cord. Once inside, the tracer travels through the fluid-filled cavities of the brain and spine, allowing a gamma camera to track its progress and detect any irregularities in how the fluid circulates.

The primary purpose of using Indium DTPA In 111 is to help diagnose conditions related to the flow and absorption of cerebrospinal fluid. It is frequently employed to locate the site of a cerebrospinal fluid leak or to investigate the causes of hydrocephalus, a condition involving an accumulation of fluid in the brain. Additionally, healthcare providers use this medication to verify that surgical shunts intended to redirect excess fluid are working properly. By mapping the specific path of the radioactive tracer, doctors can identify blockages or structural defects that might be contributing to neurological symptoms.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Indium DTPA In 111. Official source: DailyMed (NLM) · Label effective Jan 10, 2024

Indications and usage
INDICATIONS AND USAGE Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.
Dosage and administration
DOSAGE AND ADMINISTRATION Extreme care must be exercised to assure aseptic conditions in intrathecal injections. The maximum recommended intrathecal dose in the average patient (70 kg) is 18.5 MBq, 500 µ Ci. The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Contraindications
CONTRAINDICATIONS None known.
Warnings
WARNINGS The contents of the vial are radioactive. Adequate shielding of the preparation must be maintained at all times. Since the drug is excreted by the kidneys, caution should be exercised in patients with severely impaired renal function.
Adverse reactions
ADVERSE REACTIONS Aseptic meningitis and pyrogenic reactions have been rarely (less than 0.4%) observed following cisternography with Pentetate lndium Disodium In 111. One death has been reported to have occurred within 20 minutes following the administration of Pentetate Indium Disodium In 111 and appears to be drug related. In addition, two cases of septic meningitis have also been reported. There have also been reports of skin reactions and vomiting following administration of Pentetate lndium Disodium In 111. Relationship of the drug to these latter occurrences has not been established.
Use in pregnancy
Pregnancy Category C Animal reproduction studies have not been conducted with GE Healthcare (Medi-Physics, Inc.) Indium DTPA In 111. Also, it is not known whether Pentetate Indium Disodium In 111 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pentetate Indium Disodium In 111 should be given to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.